MX2015000334A - Derivado de benzodioxol y metodo de preparacion y uso del mismo. - Google Patents

Derivado de benzodioxol y metodo de preparacion y uso del mismo.

Info

Publication number
MX2015000334A
MX2015000334A MX2015000334A MX2015000334A MX2015000334A MX 2015000334 A MX2015000334 A MX 2015000334A MX 2015000334 A MX2015000334 A MX 2015000334A MX 2015000334 A MX2015000334 A MX 2015000334A MX 2015000334 A MX2015000334 A MX 2015000334A
Authority
MX
Mexico
Prior art keywords
preparation
formula
benzodioxole derivative
benzodioxole
derivative
Prior art date
Application number
MX2015000334A
Other languages
English (en)
Other versions
MX357774B (es
Inventor
Hua Bai
Xuyang Zhao
Jinqing Zhong
Yongxiang Gong
Qifeng Zhu
Xiaoyu Liu
Xiaohe Zheng
Lifei Liu
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of MX2015000334A publication Critical patent/MX2015000334A/es
Publication of MX357774B publication Critical patent/MX357774B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente invención se proporcionan derivados de benzodioxol novedosos y métodos de preparación de los mismos. Estos compuestos representados por la fórmula (I) o sales farmacéuticamente aceptables de los mismos tienen actividad inhibidora de acetilcolinesterasa, de modo que pueden usarse en el tratamiento o la prevención de la enfermedad de Alzheimer. Las definiciones de R1, R2 y A de la fórmula (I) pueden verse en la descripción. (ver Fórmula).
MX2015000334A 2012-07-03 2013-07-03 Derivado de benzodioxol y metodo de preparacion y uso del mismo. MX357774B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210226125.7A CN103524515B (zh) 2012-07-03 2012-07-03 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
PCT/CN2013/000813 WO2014005421A1 (zh) 2012-07-03 2013-07-03 苯并间二氧杂环戊烯衍生物及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2015000334A true MX2015000334A (es) 2015-04-14
MX357774B MX357774B (es) 2018-07-24

Family

ID=49881293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000334A MX357774B (es) 2012-07-03 2013-07-03 Derivado de benzodioxol y metodo de preparacion y uso del mismo.

Country Status (26)

Country Link
US (1) US9346818B2 (es)
EP (1) EP2871184B1 (es)
JP (1) JP6113275B2 (es)
KR (1) KR101650776B1 (es)
CN (2) CN103524515B (es)
AU (1) AU2013286523B2 (es)
BR (1) BR112014032964A2 (es)
CA (1) CA2878000C (es)
CL (1) CL2014003607A1 (es)
DK (1) DK2871184T3 (es)
EA (1) EA026210B1 (es)
ES (1) ES2645643T3 (es)
HK (1) HK1202857A1 (es)
IL (1) IL236395A (es)
IN (1) IN2014DN11112A (es)
MX (1) MX357774B (es)
MY (1) MY167075A (es)
NO (1) NO2871184T3 (es)
NZ (1) NZ703549A (es)
PE (1) PE20150349A1 (es)
PH (1) PH12015500012A1 (es)
PT (1) PT2871184T (es)
SG (1) SG11201500007WA (es)
UA (1) UA113444C2 (es)
WO (1) WO2014005421A1 (es)
ZA (1) ZA201500692B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
CN105859732B (zh) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
KR20190008225A (ko) * 2016-05-13 2019-01-23 델노바 인코퍼레이티드 화학적 신경차단으로 인한 부작용의 치료
CN110812358B (zh) * 2018-08-10 2022-04-05 浙江海正药业股份有限公司 化合物ad-35在治疗与胃肠蠕动障碍相关疾病中的应用
CN113185447B (zh) * 2021-05-06 2023-07-21 四川大学 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途
CN115974839B (zh) * 2021-12-24 2023-10-20 珠海市藤栢医药有限公司 AChE/SERT双靶点抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087541A (en) * 1975-03-06 1978-05-02 Boehringer Ingelheim Gmbh 2-(Aralkylaminoalkyl)phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0610496B2 (ja) * 1987-09-17 1994-02-09 ダイハツ工業株式会社 車両用自動変速機のクラッチ構造
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
KR100815772B1 (ko) * 2000-02-29 2008-03-20 미쯔비시 웰 파마 가부시키가이샤 신규 고리상 아미드 유도체
EP1468684A4 (en) * 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd SIGMA RECEPTOR BINDING MOLECULE WITH INDANO DERIVATIVE
AU2003247158A1 (en) 2003-07-01 2005-01-21 Hetero Drugs Limited Preparation of intermediates for acetyl cholinesterase inhibitors
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
EP1973878B1 (en) 2006-01-04 2010-11-24 Cipla Limited Process and intermediate for preparation of donepezil
JP2009523747A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用
CN101626688A (zh) * 2006-12-11 2010-01-13 雷维瓦药品公司 茚满酮基胆碱酯酶抑制剂的组合物、合成和使用方法
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
AU2013286523B2 (en) 2017-06-22
WO2014005421A1 (zh) 2014-01-09
CL2014003607A1 (es) 2015-03-13
CN103524515B (zh) 2016-07-06
NZ703549A (en) 2015-11-27
ZA201500692B (en) 2016-01-27
NO2871184T3 (es) 2018-02-03
MX357774B (es) 2018-07-24
EP2871184B1 (en) 2017-09-06
SG11201500007WA (en) 2015-02-27
US9346818B2 (en) 2016-05-24
EP2871184A4 (en) 2015-12-23
US20150191480A1 (en) 2015-07-09
PH12015500012B1 (en) 2015-03-02
KR101650776B1 (ko) 2016-08-25
KR20150034224A (ko) 2015-04-02
PH12015500012A1 (en) 2015-03-02
DK2871184T3 (da) 2017-11-13
CN103524515A (zh) 2014-01-22
PT2871184T (pt) 2017-11-14
IL236395A (en) 2017-01-31
EA201590074A1 (ru) 2015-07-30
IN2014DN11112A (es) 2015-09-25
ES2645643T3 (es) 2017-12-07
AU2013286523A1 (en) 2015-02-05
BR112014032964A2 (pt) 2017-06-27
JP2015525740A (ja) 2015-09-07
CA2878000C (en) 2020-05-05
IL236395A0 (en) 2015-02-26
CN104395303B (zh) 2017-12-12
MY167075A (en) 2018-08-10
JP6113275B2 (ja) 2017-04-12
EA026210B1 (ru) 2017-03-31
CA2878000A1 (en) 2014-01-09
CN104395303A (zh) 2015-03-04
EP2871184A1 (en) 2015-05-13
UA113444C2 (xx) 2017-01-25
HK1202857A1 (en) 2015-10-09
PE20150349A1 (es) 2015-02-28

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
NZ703064A (en) Inhibitors of hepatitis c virus
IN2014DN03206A (es)
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
IN2015DN01156A (es)
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20166554B (en) Nitrogenated heterocyclic compound
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
WO2013040227A3 (en) Therapeutic compounds
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
PH12015500399A1 (en) Azaindolines
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
CA2863110A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
WO2012169863A3 (en) 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
MY187891A (en) Tetrahydropyridine derivatives as fabi inhibitors
GEP201606554B (en) Nitrogenated heterocyclic compound

Legal Events

Date Code Title Description
FG Grant or registration